GlassScriptPhysician profile
Jesse Trevino
NPI 1639340144
$1,494.80
in general payments reported to CMS, 2019-2025
23 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $37.65 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $211.46 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $189.99 | 2025 | Korlym |
| Abbvie INC. | $178.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $93.01 | 2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $90.58 | 2025 | |
| Lilly USA, LLC | $85.34 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $82.56 | 2025 | Symbravo, Auvelity |
| Novo Nordisk INC | $68.14 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $66.27 | 2024-2025 | Freestyle Libre 3, Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $65.54 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $47.93 | 2025 | Rexulti |
| Amgen INC. | $45.53 | 2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.97 | 2025 | Xifaxan |
| Avvisto Therapeutics, LLC | $38.96 | 2025 | Cycloset |
| Astellas Pharma US INC | $29.06 | 2025 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.09 | 2025 | Spravato |
| Phadia US INC. | $22.15 | 2025 | Immunocap |
| Tolmar, INC. | $21.37 | 2025 | Jatenzo |
| Xeris Pharmaceuticals, INC. | $21.29 | 2025 | Recorlev |
| Noven Therapeutics, LLC | $19.96 | 2025 | Secuado, Xelstrym |
| Azurity Pharmaceuticals, INC. | $16.71 | 2025 | Edarbyclor |
| Acella Pharmaceuticals, LLC | $15.78 | 2025 | NP Thyroid 60 |
| Lundbeck LLC | $14.82 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Trevino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.